Press

COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression

May 3 • 3 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that positive data demonstrating the potential of COMP360 psilocybin therapy in anorexia nervosa and severe treatment-resistant depression has been presented at the Society of Biological Psychiatry Annual Meeting in New Orleans, from…

Field Trip Health Ltd. Announces Intention to Separate the Field Trip Discovery and Field Trip Health Divisions Into Two Independent Public Companies

May 2 • 14 min read

Field Trip Health Ltd. (TSX: FTRP | FTRP.WT | Nasdaq: FTRP), a global leader in the development and delivery of psychedelic therapies, announced today that it has received unanimous board approval to complete a reorganization that will result in the separation of its Field Trip Discovery and Field Trip Health divisions into two independent public…

Allied Corp Announces Purchase Order Continuing into Monthly Supply Agreement for Brazilian Specialty Cancer Care Hospital

Apr 29 • 2 min read

Allied Corp. (OTCQB: ALID) is pleased to announce the signing of a forward purchase agreement with a distributor for a specialty medical care hospital (the “Brazilian Group”) based out of Sao Paulo, Brazil. Under this agreement, the Brazilian Group will initially purchase US$147,000 worth of Allied products that will continue on a monthly basis. The…

Filament Health Announces Fourth Patent Issuance

Apr 28 • 2 min read

Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE:7QS), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a fourth patent for the extraction and standardization of natural psilocybin and associated psychedelic compounds. Filament’s latest patent was issued by the Canadian Intellectual Property Office (CIPO) and describes essential technology…

Phyto Partners Launches Neurowellness-Focused Venture Capital Fund

Apr 27 • 3 min read

Phyto Partners, LLC, a top venture capital fund, is launching its fourth private equity fund – Phyto IV, LP – focused on businesses operating in and around neurowellness and brain health and the use of psychedelic compounds for the improvement of mental well-being. Phyto Partners has partnered with Ambria Capital, LLC, for the management of…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435